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Abstract
Liver metastases of colorectal cancer are currently treated by multidisciplinary teams using strategies that combine
chemotherapy, surgery and ablative techniques. Many patients classically considered non-resectable can now be rescued by
neoadjuvant chemotherapy followed by liver resection, with similar results to those obtained in initial resections. While
many of those patients will recur, repeat resection is a feasible and safe approach if the recurrence is confined to the liver.
Several factors that until recently were considered contraindications are now recognized only as adverse prognostic factors
and no longer as contraindications for surgery. The current evaluation process to select patients for surgery is no longer
focused on what is to be removed but rather on what will remain. The single most important objective is to achieve a
complete (R0) resection within the limits of safety in terms of quantity and quality of the remaining liver. An increasing
number of patients with synchronous liver metastases are treated by simultaneous resection of the primary and the liver
metastatic tumours. Multilobar disease can also be approached by staged procedures that combine neoadjuvant
chemotherapy, limited resections in one lobe, embolization or ligation of the contralateral portal vein and a major resection
in a second procedure. Extrahepatic disease is no longer a contraindication for surgery provided that an R0 resection can be
achieved. A reverse surgical staged approach (liver metastases first, primary second) is another strategy that has appeared re-
cently. Provided that a careful selection is made, elderly patients can also benefit from surgical treatment of liver metastases.
Key Words: liver surgery, metastases, colorectal cancer, chemotherapy, hepatectomy, liver neoplasms (surgery), liver
neoplasms (secondary), neoplasm metastasis, survival rate, liver diseases (surgery)
Introduction
In recent years, advances in surgical techniques and
modern chemotherapy have introduced revolution-
ary changes in the multidisciplinary treatment ap-
proach to colorectal liver metastases (CLMs) [1].
The results are highly encouraging and surgeons
have the possibility to tailor the therapeutic ap-
proach according to each patient’s individual char-
acteristics. ‘Which treatment for which patient?’ is
no longer a question for the future but the current
practice in CLM.
What are the principles of indications/
contraindications for surgical treatment?
Until recently, evaluation of the liver focused on the
location and number of lesions, and disease-free
intervals. Classical contraindications for resection
included: bilobar disease, more than four lesions,
large tumours (5 or 10 cm) and extrahepatic disease
[25]. In current practice, while the prognostic
impact of these factors is acknowledged, none of
them are considered absolute contraindications for
surgery. Nowadays, the evaluation of the surgical
candidate must be conducted to determine if a
complete and safe resection can be performed [6].
Complete (R0) resection is defined as elimination of
all metastatic lesions with free margins of resection. If
the liver function is normal, and the remaining liver
will be at least 2530%, the resection can be done
safely. The San Francisco Consensus Conference [6]
represented an important shift in the focus of the
evaluation before liver resection. Instead of being
defined by what is removed, resectability should now
be determined by what will remain. This will result in
an increasing number of patients being eligible for
surgery.
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What are the factors that affect the overall
prognosis?
The overall prognosis is negatively affected by syn-
chronous presentation, CEA levels 200 ng/ml,
positive lymph nodes, serosal invasion, shorter inter-
vals in appearance of metachronous lesions, number
of lesions seen on CT scan preoperatively, resection
margins B1 cm, metastases 5 cm and bilobar
disease. These are adverse prognostic factors, not
contraindications for surgery [7].
When is the tumour burden too much for
surgery?
The tumour burden is too much for surgery only
when an R0 resection cannot be expected. In a
recently published large prospective single-centre
experience, Figueras et al. [7] suggested that liver
resection combined with preoperative and postopera-
tive chemotherapy offers the possibility of long-term
survival to patients with multiple, bilateral, large
CLMs, even with resectable extrahepatic disease.
Surgery should be offered to patients with expanded
indications because hepatic resection may increase
longevity and improve quality of life in selected
patients with CLM.
What is the current impact of the surgery of
CLM?
Surgical resection is presently the only approach
that offers patients with CLM a substantial chance
of cure. Resection of CLM is safe and effective;
it should be considered the treatment of choice for
this disease and proposed even for advanced lesions.
The survival rate of patients who undergo a complete
resection is about 40% at 5 years. Operative mortality
within 2 months should be B5%, and postopera-
tive morbidity was 28% in the experience of Figueras
et al. [7].
What to do with patients with colorectal liver
metastases who present with unresectable
disease at the time of diagnosis?
Most patients with CLM will present with unresect-
able disease at the time of diagnosis. The current
definition of unresectable includes: 70% of the
liver affected or more than six segments. Other
causes of unresectability are invasion of both portal
branches or the three hepatic veins. Those patients
who present with unresectable disease can be
rescued by neoadjuvant chemotherapy. The prog-
nosis of unresectable CLM might be improved if a
radical surgical resection (rescue surgery) of CLM
could be performed after a response to chemother-
apy [8,9].
What is the role of neoadjuvant chemotherapy?
Unresectable disease is the most frequent presenta-
tion in patients with CLM. Bismuth et al. [8] in 1990
reported patients who had a significant down-sizing of
their hepatic lesions with neoadjuvant chemotherapy.
Those patients were then brought to surgery for an
attempted R0 resection, obtaining a 5-year survival
rate of 28%. Mortality and morbidity were similar to
those resected de novo. These results represented a
revolution in liver surgery [10].
How to combine neoadjuvant chemotherapy and
surgical treatment?
Those patients initially classified as unresectable
should be re-evaluated for resectability after neoadju-
vant therapy [1121]. One strategy consists of using
four to six cycles of one of the newer effective
chemotherapeutic combinations such as FOLFOX
or FOLFIRIBevacizumab or Cetuximab and re-
evaluation of resectability. Do not use excessive
number of cycles of chemotherapy because important
liver steatohepatitis can develop [22,23]. A recent
report suggested that vascular complications mani-
festing as sinusoidal obstruction are a prominent
feature in chemotherapy-induced liver toxicity
[24,25]. The combination of steatosis and sinusoidal
obstruction greatly enhances the risk of serious
intraoperative bleeding. Another important notion is
that complete radiological response must not be
achieved because it produces great difficulty at the
time of mapping for surgical resection. Besides that,
complete radiological response almost always is asso-
ciated with recurrence [26]. At the time of planning
the surgical resection, the CT image that must be
taken into account is the first one rather than that
following chemotherapy. Hepatic surgery should be
performed as soon as the disease becomes resectable.
The patient must be operated during the therapeutic
window provided by the response to chemotherapy.
Otherwise we will be operating a patient during
tumour progression and the results will be poor
[27]. The surgical procedure must be scheduled 68
weeks after the discontinuation of Bevacizumab. This
period of 68 weeks is important so as to avoid the
complications produced by the antiangiogenic effects
of Bevacizumab [28], although another report did not
find any increase in the morbidity following hepatect-
omy with the perioperative use of Bevacizumab [29].
Alternatively one or two cycles of FOLFOX or
FOLFIRI without Bevacizumab can be administered
during this period before surgery. Modern che-
motherapy allows 1750% of patients with unresect-
able CLM to be rescued by liver surgery [9]. Despite a
high rate of recurrence, 5-year survival is 33% overall,
with a wide use of repeat hepatectomies and extra-
hepatic resections.
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Is surgery of CLM indicated in patients with
progression of the tumours while on neoadjuvant
chemotherapy?
In this clinical scenario surgery must not be carried
out. Liver resection is able to offer long-term survival
to patients with multiple CLMs provided that the
metastatic disease can be controlled by chemotherapy
before surgery. Tumour progression before surgery is
associated with a poor outcome, even after potentially
curative hepatectomies. Tumour control before sur-
gery is crucial to offer a chance of prolonged remission
in patients with multiple metastases [27].
How many patients with colorectal cancer who
have undergone ‘curative’ hepatic resection will
develop recurrences?
At least 6080% of patients who undergo a hepatic
resection for CLM will develop a local, regional or
distant recurrence. Those recurrences must be ex-
pected in the 30 months that follow the resection,
with 85% of the recurrences occurring in this period.
In 30% of those patients that recur the metastases are
confined to the liver. In these patients a repeat
resection or an ablation procedure must be considered
[30].
Are repeat resections a safe approach?
This approach is possible due to the regeneration
capacity of the liver [3133]. It takes 36 weeks for
the liver to regenerate to its presurgical volume.
Mortality, morbidity and survival are similar to those
following the initial resection. Combined extrahepatic
surgery can be required to achieve tumour era-
dication. Repeat hepatectomies appear worthwhile
when potentially curative [3437]. The definition of
‘potentially curative’ includes: margins of resection
free of disease and resection of extrahepatic disease.
In repeat resections the general rule also applies that it
does not matter how many lesions the patient has
provided that an R0 resection can be achieved within
limits of safety in terms of liver volume and function.
Based on this, the new trends in surgical evaluation
now focus on whether a complete resection can be
safely performed. The risk factors associated with
poorer prognosis in second and third resections are
similar to those for primary resections: number of
tumours resected, the size of the largest lesion, bilobar
involvement, and positive margins. The most impor-
tant ominous factor is the presence of positive
margins.
Can surgical resection be combined with
ablative techniques?
At present, radiofrequency ablation (RFA) is the most
widely used technique of liver ablation [3846].
Recent reports showed that it is especially useful for
lesions smaller than 3 cm and located at a certain
distance from the important vessels [47,48]. This
is a serious limitation of RFA: the dissipation of
heat produced by the blood flow in an adjacent
vessel greatly diminishes its efficacy. Intraoperative
use of RFA is an important tool in achieving an
R0 resection in cases otherwise considered unresect-
able [49,50]. In this sense, RFA increased the number
of patients who can be surgically treated. In cases
of recurrences, some authors prefer percutaneous
RFA to repeat hepatectomy when feasible and
safe because it is less invasive, using repeat hepatect-
omy only when RFA is contraindicated or fails [51].
RFA is safe and as effective as surgical resection
in prolonging survival in patients with lesions B3 cm.
For lesions 3 cm, surgery must be preferred when-
ever possible.
Two-stage hepatectomy: how can it be integrated
in a multimodal treatment approach?
In cases of multiple, bilateral, unresectable CLMs,
the strategy must be multimodal  starting with
neoadjuvant chemotherapy. In patients with a nor-
mal liver, portal vein embolization (PVE) is indi-
cated when the future liver remnant volume is
predicted to be B30% [5266]. PVE may also be
useful in patients who have evidence of chemother-
apy-related liver injury. If there is a positive
response to chemotherapy, then surgery could be
used [27]. In a first stage, limited resection of CLM
in one lobe is performed combined with RFA of
other lesions and PVE of the contralateral portal
vein. Alternatively, ligation and alcoholization of the
portal vein can be performed intraoperatively. PVE,
ligation and/or alcoholization produces, on the one
hand, an important atrophy of the implicated lobe,
and on the other hand, a significant hypertrophy of
the contralateral lobe. This is a strategy to enhance
the volume of the future remnant liver. Studies
have shown an approximately 1025% increase in
the size of the liver remnant after PVE [5266].
This hypertrophy is complete by the third week. In
a second stage, a major resection of the contralateral
liver can be carried out in conditions of safety
[6769]. Usually, those patients will receive post-
operative chemotherapy. With this approach, cur-
rently there are no limits to resection other than
those imposed by the volume and function of the
remnant liver.
Combined or staged procedures in the treatment
of synchronous CLMs?
The optimal timing of the surgical treatment of syn-
chronous CLM is a matter of controversy [7086].
Studies that compared combined versus staged pro-
cedures demonstrated that the overall survival is
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similar, but the complication rate for the combined
procedure was significantly less than for a staged
procedure [70,71]. However, combined procedures
tended to include more right colectomies and more
limited hepatic resections. Staged procedures tended
to include more difficult low anterior or abdominal
perineal resections or major liver resections. In highly
specialized centres there is a trend toward combined
procedures whenever possible, because simultaneous
liver resection is safe, avoids two operations, avoids
the possible hepatotoxicity of neoadjuvant chemother-
apy, and allows resection of CLM that may ultimately
metastasize further [71]. In our experience with 61
patients undergoing simultaneous liver and colorectal
resection this approach was safe and had similar
short- and long-term results to staged procedures in
this carefully selected group of patients [87]. The
most important factor in selection of patients for
combined resection in our series was the extent of
liver to be resected. It is our policy to avoid combined
resection in those patients who need a major liver
resection.
Staged surgery: which procedure first? The
reverse approach
The classic staged surgical approach consists of
treatment of the primary followed by treatment
of the CLM. However, in many patients with
advanced synchronous CLMs, the metastases pro-
gress during treatment of the primary, precluding
curative treatment. Based on this observation,
Mentha et al. [88] designed a management strategy
that involves high-impact chemotherapy first, resec-
tion of CLM second and finally removal of the
primary tumour in those patients with adverse prog-
nostic factors. In the experience of these authors,
this new ‘reverse’ approach produced resectability
and survival rates better than those expected from
the published data on patients with disease of
similar severity. The obvious candidate for this
novel approach would be a patient with non-
obstructive primary colonic tumour. The rationale
for the reverse approach is that the lesion that kills
the patient is the metastasis.
Is there any role for trans-metastases
hepatectomy?
In the setting of multiple, bilateral, unresectable
CLMs, sometimes a situation exists in which the
only possible future hepatectomy plane passes
through a liver metastasis. Elias et al. [89,90] pro-
posed a new curative technical approach to these
patients. Firstly, the ill-sited LM, which is located in
the only feasible future resection plane, is ablated
using RF, then the hepatectomy is performed through
this ablated LM. According to these authors, this is a
safe and useful technique.
What is the role of an R0 resection regarding
prognosis?
Many of the factors that affect the overall prognosis
do that by making R0 resection difficult to achieve
[9194]. But, if an R0 resection can be achieved, they
lose their negative impact on survival. Studies showed
significant 5-year survival rates in patients with more
than four lesions if an adequate R0 surgical resection
was performed [91]. If metastases can be resected
completely with sufficient remaining liver, it does not
matter how many lesions the patient has. Similar
considerations can be made regarding the size of the
metastatic lesions, the synchronous appearance, a
disease-free interval B1 year in the appearance of
metachronous lesions, and bilobar involvement [7]. In
summary, at present, the only major predictor of
prognosis is an R0 resection.
Free margins. Is the 1 cm rule still valid?
The single most important factor that negatively
affects the prognosis after resection is the involve-
ment of the resection margin for the tumour
[9194]. Classically, a 1 cm margin has been
considered necessary to avoid liver recurrence. The
importance of this factor is enhanced by the fact that
it is the only factor that could be directly influenced
by the surgeon. This was a matter of controversy for
many years. In a large series recently reported by
Figueras et al. [95], sub-centimetre non-positive
resection margin failed to show any influence as an
independent factor on liver recurrence. Currently,
most authors agree that an expected resection margin
B1 cm must not preclude the indication for surgery
[9698].
Is the presence of extrahepatic disease an
absolute contraindication for liver resection?
For many years extrahepatic disease has been
accepted as a contraindication to liver resection.
Recently a 5-year survival rate of 1237% following
liver resection was reported in selected patients with
extrahepatic disease [99]. This benefit was indepen-
dent of the location of the disease (lung, primary
colorectal recurrence, retroperitoneal or hepatic
pedicle lymph nodes, peritoneal carcinomatosis,
miscellaneous). Currently, the presence of extrahe-
patic disease is no longer considered an absolute
contraindication to hepatic resection. A careful
selection of patients must be conducted. The
minimum requirements are: responsive disease
with chemotherapy and the expectation of an
R0 resection. However, patients with tumoral inva-
sion of the lymph nodes in the hepatic pedicle,
particularly if the celiac nodes are affected, have
poorer prognosis than those with solitary pulmonary
metastases.
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Resection of isolated pulmonary recurrence
after resection of colorectal liver metastases.
Is it a worthwhile operation?
Prolonged survival can be achieved with resection of
isolated pulmonary recurrence after hepatic resection
for CLM [100102]. Studies conducted to identify a
subgroup of patients who best benefit from hepatic
and pulmonary metastasectomy among those with
colorectal carcinoma metastases identified sequential
detection of hepatic and pulmonary metastases as the
strongest independent favourable prognostic factor.
Patients with sequentially detected hepatic and pul-
monary metastases from a colorectal primary are good
candidates for aggressive metastasectomy. Simulta-
neous detection of these metastases does not warrant
resection [103].
Can elderly patients benefit from surgical
treatment of liver metastases?
Yes, elderly patients can definitely benefit from
surgical treatment of liver metastases. In our experi-
ence the elderly have a higher mortality after surgical
treatment of CLM compared with the younger group
[104]. In recent years, however, that difference was
markedly reduced  probably due to improvements in
perioperative care. The performance of major liver
resections increased the mortality in the elderly. If the
postoperative mortality is excluded, the results in
terms of survival and disease-free survival are similar
in both groups [104117]. Therefore, the criteria on
which the indication for surgery in the elderly is based
must be the same as those for the rest of the
population [105].
Conclusions
Treatment of CLM is a dynamic and continuously
evolving field. At present, the multimodal treatment
approach allows us to individualize the treatment
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